Dual HER2 and TROP2 Antibody–Drug Conjugates Overcome Tumor Heterogeneity in Breast Cancer

Breast cancer is not a single disease but a collection of many different conditions, each with its own unique molecular fingerprint. For decades, doctors have treated these tumors by targeting specific proteins on the surface of cancer cells, much like using a key to unlock a specific door. One of the most famous keys targets a protein called HER2, while another targets a protein known as TROP2. When a drug successfully finds its matching protein, it delivers a toxic payload directly into the cell, killing it. However, these treatments face a persistent problem: tumors are rarely uniform. Inside a single tumor, some cells might display the HER2 keyhole, others might show TROP2, and many might show neither. This uneven landscape allows cancer cells to hide from treatment, leading to resistance and the return of the disease. The central challenge for modern oncology is finding a way to cover this entire, shifting terrain rather than just a small patch of it.

Researchers at the Centre de Recherche en Cancérologie de Marseille set out to solve this puzzle by testing a strategy of dual targeting. Instead of relying on a single key, they asked whether using two different antibody-drug conjugates at the same time could overcome the tumor's ability to hide. An antibody-drug conjugate is a sophisticated weapon that combines a targeting antibody with a potent chemotherapy drug. The team focused on combining a drug that targets HER2 with another that targets TROP2. They began their investigation in the laboratory, treating three different types of breast cancer cells with these drugs, both alone and in combination. The results were striking. When the two drugs were used together, they worked far better than the sum of their individual parts. Even at concentrations that are safe and achievable in human patients, the combination killed significantly more cancer cells than either drug could manage on its own. This synergy suggested that the two drugs were not just fighting side by side, but were actively helping each other succeed.

To understand why this combination worked so well, the scientists looked deeper into the biology of real human tumors. They analyzed gene expression data from over 13,000 primary breast cancer samples. At the level of the whole tumor, they found that the two targets were complementary. While about 34 percent of tumors expressed TROP2 and 22 percent expressed HER2, nearly half of all tumors expressed at least one of the two. Crucially, many tumors that lacked one target possessed the other. This meant that a treatment strategy using both drugs could theoretically reach 47 percent of tumors, a substantial increase over using just one. However, looking at the tumor as a whole was not enough to explain the full picture. Tumors are complex ecosystems where different types of cells live side by side.

To see this complexity, the researchers examined more than 200,000 individual cancer cells from 112 patients. They discovered that within a single tumor, there is a chaotic mix of cell types. Some cells carried only HER2, others only TROP2, some carried both, and many carried neither. This internal diversity is what allows cancer to survive single-target therapies; if a drug kills only the HER2 cells, the TROP2 cells remain to regrow the tumor. The study revealed that by using both drugs simultaneously, doctors could theoretically target a much larger portion of the cells within a single patient's tumor. On average, this dual approach increased the number of targetable cells by 13 percent per patient, with some patients seeing a much larger gain. This finding suggests that the combination therapy does not just broaden the net; it also increases the intensity of the attack on cells that happen to carry both targets, potentially delivering a heavier dose of the toxic payload.

The researchers did not stop at genetic data; they also looked at the physical arrangement of these cells in tissue samples from eight patients. Using advanced imaging techniques, they mapped the location of every cell and observed how the different types were organized. They found that the cells were not randomly scattered. Sometimes, cells with the same target formed distinct clusters or "niches," while at other times, cells with different targets were intermixed like a mosaic. This spatial organization matters because it influences how the drugs interact with the tumor. If cells are intermixed, a drug targeting one type might be able to kill its neighbor through a "bystander effect," where the toxic payload leaks out and kills nearby cells that lack the target. The study confirmed that the physical layout of the tumor varies greatly from patient to patient, adding another layer of complexity to how these treatments should be designed.

Despite these promising findings, the authors are careful to note that this is a preclinical study. The synergy was demonstrated in cell cultures, and the expression patterns were derived from existing data and a small number of tissue samples. The study does not yet prove that this approach will cure patients or that it is safe to use these powerful drugs together in humans. Combining two potent therapies carries the risk of increased side effects, and the optimal way to administer them is still unknown. However, the biological evidence is strong enough to justify moving forward. Based on these results, the researchers have already launched a clinical trial to test an alternating schedule of these two drugs in patients with advanced breast cancer. The goal is to see if this strategy can prevent the cancer from developing resistance and improve survival rates. The work highlights a shift in thinking: rather than trying to find a single perfect target for every patient, the future of cancer treatment may lie in understanding the unique, heterogeneous landscape of each tumor and using a combination of tools to cover the entire ground.